Similar Datasets
Project description:Regulatory variants associated with canine hematopoietic cancers
| PRJNA687525 | ENA
Project description:Transcriptome analysis of lymphoma samples were performed to assess EGFR and PLAUR/uPAR expression profiles and compare to human tumors from TCGA. Abstract Sarcomas differ from carcinomas in their mesenchymal origin. Therapeutic advancements have come slowly so alternative drugs and models are urgently needed. These studies report a new drug for sarcomas that simultaneously targets both tumor and tumor neovasculature. eBAT is a bispecific angiotoxin consisting of truncated, deimmunized Pseudomonas exotoxin fused to epidermal growth factor (EGF) and the amino terminal fragment (ATF) of urokinase. Here, we study the drug in an in vivo “ontarget” companion dog trial since eBAT effectively kills canine hemangiosarcoma (HSA) and human sarcoma cells in vitro. We reasoned the model has value due to the common occurrence of spontaneous sarcomas in dogs and a limited lifespan allowing for rapid accrual and data collection. Splenectomized dogs with minimal residual disease were given one cycle of eBAT followed by adjuvant doxorubicin in an adaptive dose-finding, phase I- II study of 23 dogs with spontaneous, stage I-II, splenic HSA. eBAT improved 6-month survival from <40% in a comparison population to ~70% in dogs treated at a biologically active dose (50 μg/kg). Six dogs were long-term survivors, living >450 days. eBAT abated expected toxicity associated with EGFR-targeting, a finding supported by mouse studies. Urokinase plasminogen activator receptor (uPAR) and EGFR are targets for human sarcomas, so thorough evaluation is crucial for validation of the dog model. Thus, we validated these markers for human sarcoma targeting in the study of 212 human and 97 canine sarcoma samples. Our results support further translation of eBAT for human patients with sarcomas and perhaps other EGFR-expressing malignancies.
2017-02-23 | GSE95184 | GEO
Project description:Transcriptome analysis of hemangiosarcoma samples were performed to assess EGFR and PLAUR/uPAR expression profiles and compare to human tumors from TCGA. Abstract Sarcomas differ from carcinomas in their mesenchymal origin. Therapeutic advancements have come slowly so alternative drugs and models are urgently needed. These studies report a new drug for sarcomas that simultaneously targets both tumor and tumor neovasculature. eBAT is a bispecific angiotoxin consisting of truncated, deimmunized Pseudomonas exotoxin fused to epidermal growth factor (EGF) and the amino terminal fragment (ATF) of urokinase. Here, we study the drug in an in vivo “ontarget” companion dog trial since eBAT effectively kills canine hemangiosarcoma (HSA) and human sarcoma cells in vitro. We reasoned the model has value due to the common occurrence of spontaneous sarcomas in dogs and a limited lifespan allowing for rapid accrual and data collection. Splenectomized dogs with minimal residual disease were given one cycle of eBAT followed by adjuvant doxorubicin in an adaptive dose-finding, phase I- II study of 23 dogs with spontaneous, stage I-II, splenic HSA. eBAT improved 6-month survival from <40% in a comparison population to ~70% in dogs treated at a biologically active dose (50 μg/kg). Six dogs were long-term survivors, living >450 days. eBAT abated expected toxicity associated with EGFR-targeting, a finding supported by mouse studies. Urokinase plasminogen activator receptor (uPAR) and EGFR are targets for human sarcomas, so thorough evaluation is crucial for validation of the dog model. Thus, we validated these markers for human sarcoma targeting in the study of 212 human and 97 canine sarcoma samples. Our results support further translation of eBAT for human patients with sarcomas and perhaps other EGFR-expressing malignancies.
2017-02-23 | GSE95183 | GEO
Project description:Some dogs respond well to amputation and chemotherapy and are disease free longer than the median 200 days whereas others experience rapid lung metastasis. Microarrays were used to compare primary tumors of dogs with a disease free interval (DFI) >300 days (n=7) to those with a DFI<100 days (n=8). Chemotherapy naïve primary tumors were collected at the time of amputation and archived at the Animal Cancer Center. Arrays were performed on a total of 15 dogs.
2010-09-22 | E-GEOD-24251 | biostudies-arrayexpress
Project description:Some dogs respond well to amputation and chemotherapy and are disease free longer than the median 200 days whereas others experience rapid lung metastasis. Microarrays were used to compare primary tumors of dogs with a disease free interval (DFI) >300 days (n=7) to those with a DFI<100 days (n=8).
2010-09-22 | GSE24251 | GEO
Project description:The aim of this work was to identify the copy number aberrations (CNAs) by high-resolution array comparative genomic hybridization (aCGH) on 7 dogs with newly diagnosed FL and 5 dogs with newly diagnosed MZL.
2020-06-30 | GSE131618 | GEO
Project description:VSV-IFNβ-NIS is a recombinant oncolytic vesicular stomatitis virus (VSV) that is being evaluated clinically for the treatment of advanced malignancies. As with other cancer immunotherapies, identifying biomarkers of response will be critical to the clinical advancement of this treatment approach. . RNAseq analysis showed that virtually all the long-term responders had increased expression of a CD8 T-cell anchored immune gene cluster. We conclude that neoadjuvant VSV-IFNβ-NIS has an excellent safety profile and may provide a survival benefit for dogs with osteosarcoma whose tumors are permissive for immune infiltration.
2023-10-01 | GSE240033 | GEO
Project description:Comparison of the gene expression profile in lungs from dogs with spontaneous canine idiopathic pulmonary fibrosis and from control dogs with histologically normal lungs.
2013-10-01 | E-MEXP-3671 | biostudies-arrayexpress
Project description:Identification of canine regulatory regions in peripheral blood mononuclear cells from purebred dogs.
2021-04-13 | GSE163779 | GEO
Project description:To investigate the potential regulatory mechanism of pyogenesis in dogs, we conducted transcriptome sequencing analysis on the uterus of pyogenesis dogs and healthy dogs, and the results showed that there were 11812 differentially expressed genes in pyogenesis dogs compared with healthy dogs, among which 7086 genes were up-regulated in utero and 4726 genes were down-regulated. And most of these genes are involved in immune and inflammatory responses.
2023-07-04 | GSE208124 | GEO